Related Experiment Video
Updated: Jul 18, 2026
13:08
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Risedronate: a new oral bisphosphonate
1Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania 19104, USA.
Clinical Therapeutics
|October 9, 2001
Summary
Risedronate effectively treats osteoporosis and Paget's disease, showing comparable efficacy to alendronate but with better gastrointestinal tolerability. Further studies are needed to define its optimal role in bone disease therapy.
Area of Science:
- Pharmacology and Therapeutics
- Bone Metabolism and Disease
Background:
- Bisphosphonates are established treatments for osteoporosis and Paget's disease.
- Risedronate is a newer oral bisphosphonate approved for postmenopausal and glucocorticoid-induced osteoporosis, and Paget's disease.
Purpose of the Study:
- To review current studies on risedronate for osteoporosis and Paget's disease.
- To compare risedronate with other bisphosphonates and therapies.
- To review risedronate's pharmacokinetics, adverse effects, and use in other disorders.
Main Methods:
- Searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts (1966-2000).
- Inclusion of English-language clinical studies and review articles.
- Use of search terms: risedronate, NE 58095, bisphosphonates, alendronate, osteoporosis, Paget's disease.
Main Results:
- Risedronate increases bone mineral density (BMD) and reduces fractures in postmenopausal osteoporosis.
- In glucocorticoid-induced osteoporosis, risedronate increases BMD but fracture risk reduction is inconsistent.
- Risedronate shows potential advantages over etidronate and alendronate regarding BMD, fracture risk, and gastrointestinal tolerability.
Conclusions:
- Risedronate is comparable to alendronate for osteoporosis and Paget's disease treatment efficacy.
- Risedronate may be preferred over alendronate due to better gastrointestinal tolerability.
- Further comparative and pharmacoeconomic studies are required to establish risedronate's definitive therapeutic position.
Related Concept Videos
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:31Essential Minerals for Bone Health
The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...